Brentuximab vedotin for Hodgkin lymphoma in children and young adults
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 2 to under 35 years old
- You must have been diagnosed with classical Hodgkin lymphoma by at least two hospitals
- Your organs must be working well enough for treatment
- You or your guardian must agree to join the study
- You cannot have nodular lymphocyte-predominant Hodgkin lymphoma
- You cannot be pregnant, breastfeeding, or have an immune problem like HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with a type of lymphoma called EBV-positive DLBCL that has not been treated before. The goal is to see if adding brentuximab vedotin to the standard R-CHP chemotherapy can improve outcomes.
This trial tests whether giving a drug called brentuximab vedotin after a stem cell transplant can help keep your lymphoma in check and prevent it from coming back. It is for people with a specific type of lymphoma (mycosis fungoides) that has been hard to treat and who have recently had a transplant.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.